Jump Financial LLC Buys Shares of 11,507 Disc Medicine, Inc. (NASDAQ:IRON)

Jump Financial LLC purchased a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,507 shares of the company's stock, valued at approximately $730,000.

Several other hedge funds and other institutional investors have also modified their holdings of IRON. Geode Capital Management LLC boosted its stake in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after purchasing an additional 70,983 shares during the period. Barclays PLC raised its holdings in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company's stock valued at $1,972,000 after buying an additional 22,202 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Disc Medicine during the fourth quarter worth approximately $5,479,000. Raymond James Financial Inc. bought a new position in Disc Medicine in the 4th quarter worth approximately $5,579,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Disc Medicine in the 4th quarter valued at approximately $235,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on IRON shares. HC Wainwright reissued a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Wedbush reissued an "outperform" rating and set a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. TD Cowen began coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating on the stock. Finally, Cantor Fitzgerald upped their target price on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $93.80.

Disc Medicine Stock Performance

NASDAQ IRON opened at $44.01 on Wednesday. Disc Medicine, Inc. has a 1 year low of $25.64 and a 1 year high of $68.73. The business's fifty day moving average is $49.07 and its two-hundred day moving average is $55.12. The stock has a market capitalization of $1.52 billion, a P/E ratio of -11.06 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $55.54, for a total transaction of $416,550.00. Following the transaction, the insider now directly owns 14,035 shares in the company, valued at approximately $779,503.90. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mona Ashiya sold 202,146 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34. Following the completion of the sale, the director now owns 208,742 shares of the company's stock, valued at $11,332,603.18. The trade was a 49.20 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 361,690 shares of company stock valued at $19,648,094. 4.24% of the stock is currently owned by corporate insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.